Compare VEL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VEL | OABI |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.2M | 773.1M |
| IPO Year | 2019 | 2021 |
| Metric | VEL | OABI |
|---|---|---|
| Price | $15.94 | $4.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.83 | $8.33 |
| AVG Volume (30 Days) | 146.9K | ★ 1.5M |
| Earning Date | 11-04-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.98 | 6.56 |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $94.10 |
| Revenue Next Year | $11.91 | $30.33 |
| P/E Ratio | $8.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.18 | $1.35 |
| 52 Week High | $21.40 | $5.45 |
| Indicator | VEL | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 50.07 |
| Support Level | $14.22 | $4.43 |
| Resistance Level | $18.15 | $5.30 |
| Average True Range (ATR) | 0.76 | 0.38 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 27.15 | 51.36 |
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.